Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls
Top Cited Papers
Open Access
- 10 March 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (11)
Abstract
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS), which is linked to Epstein–Barr virus (EBV) infection, preceding the disease. The molecular mechanisms underlying this connection are only partially understood. We previously described molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and three human CNS proteins: anoctamin-2 (ANO2), alpha-B crystallin (CRYAB), and glial cellular adhesion molecule (GlialCAM). Here, we investigated antibody responses against EBNA1 and GlialCAM in a large cohort of 650 MS patients and 661 matched population controls and compared them to responses against CRYAB and ANO2. We confirmed that elevated IgG responses against EBNA1 and all three CNS-mimic antigens associate with increased MS risk. Blocking experiments confirmed the presence of cross-reactive antibodies and molecular mimicry between EBNA1 and GlialCAM, and accompanying antibody responses against adjacent peptide regions of GlialCAM suggest epitope spreading. Antibody responses against EBNA1, GlialCAM, CRYAB, and ANO2 are elevated in MS patients carrying the main risk allele HLA-DRB1*15:01, and combinations of HLA-DRB1*15:01 with anti-EBNA1 and anti-GlialCAM antibodies increase MS risk significantly and in an additive fashion. In addition, antibody reactivities against more than one EBNA1 peptide and more than one CNS-mimic increase the MS risk significantly but modestly. Overall, we show that molecular mimicry between EBNA1 and GlialCAM is likely an important molecular mechanism contributing to MS pathology.Keywords
Funding Information
- HHS | NIH (R01 AI173189)
- Swedish Research Council (2020-01638)
- Swedish Brain Foundation and Horizon Europe (101137154)
- the Swedish Research Council (n/a)
- the Knut and Alice Wallenberg Foundation (n/a)
- The Swedish Brain Foundation (n/a)
- Margaretha af Ugglas foundation (n/a)
- US Army Medical Research Acquisition Activity (HT9425-23-1-0595)
- Gunvor and Josef Anérs Foundation (n/a)
- NEURO Stockholm, MS Forskningsfonden (n/a)
- NEURO Sweden (n/a)
- Stanford School of Medicine Dean's Postdoctoral Fellowship (n/a)
- the NIH (5T32AR050942-18)
- National Institute of Allergy and Infectious Diseases (1K23AI177932-01A1)
This publication has 51 references indexed in Scilit:
- Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple SclerosisJAMA Neurology, 2024
- Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosisCell, 2023
- Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanismClinical & Translational Immunology, 2023
- Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenanceCell, 2021
- Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15European Journal of Immunology, 2020
- Treatment of Multiple Sclerosis: A ReviewThe American Journal of Medicine, 2020
- Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine modelJournal of Autoimmunity, 2020
- No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosisJournal of Clinical Virology, 2010
- Antibodies to specific EBNA-1 domains and HLA DRB1⁎1501 interact as risk factors for multiple sclerosisJournal of Neuroimmunology, 2009
- Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic proteinCell, 1995